FDA Approps Amendment Targets Chief Counsel Troy; Pfizer Ties Challenged
This article was originally published in The Pink Sheet Daily
Executive Summary
Amendment by Rep. Hinchey moves $500,000 from Chief Counsel's office to CDER's ad division. Troy wasted taxpayer money and undermined FDA's mission by intervening in state civil cases against drug and device manufacturers, Hinchey asserts.
You may also be interested in...
Rep. Hinchey Calls On FDA To Investigate Agency Knowledge Of Prozac Data
Rep. Maurice Hinchey (D-N.Y.) requests that FDA conduct an investigation into what the agency did or did not know about Lilly documents regarding a possible link between Prozac (fluoxetine) and increased suicidality and violence
Rep. Hinchey Calls On FDA To Investigate Agency Knowledge Of Prozac Data
Rep. Maurice Hinchey (D-N.Y.) requests that FDA conduct an investigation into what the agency did or did not know about Lilly documents regarding a possible link between Prozac (fluoxetine) and increased suicidality and violence
“Missing” Lilly Documents Under Review By Rep. Hinchey
The documents allegedly suggest that Lilly was aware of a link between Prozac and suicidality as early as the 1980s. Hinchey is expected to issue a statement regarding the documents by Jan. 7.